Beyond the primary battle against tumors, many cancer patients face a debilitating secondary war against cachexia, a profound wasting syndrome that silently erodes the body and spirit. This severe metabolic condition, marked by unintentional weight loss and muscle deterioration, significantly
In the high-stakes world of biopharmaceutical development, the line between a groundbreaking success and a costly failure is often defined by the unforgiving logic of statistical significance, a reality Nektar Therapeutics recently confronted with its autoimmune drug, rezpegaldesleukin. The company
The intricate dance of cellular machinery required to produce life-saving biologic therapies has long been dictated by a rhythm of chance, but a new era of genomic precision is fundamentally changing the tempo of drug development. For decades, the biopharmaceutical industry has grappled with a
The landscape of cancer immunotherapy was shaken as Arcus Biosciences announced the termination of a pivotal Phase 3 trial for its TIGIT-targeting drug, domvanalimab. The decision, prompted by a finding of "futility," delivers a significant setback to its partner Gilead Sciences and casts further
The translation of profound academic research into tangible technologies that address humanity's most pressing challenges stands as a hallmark of institutional excellence, a commitment exemplified by the University of California, Los Angeles. In a significant recognition of this mission, two
The journey to bring a new medicine to market is a monumental undertaking, frequently spanning over a decade and consuming more than two billion dollars in investment, a reality that has long created a significant bottleneck in addressing pressing global health challenges. In this high-stakes
